In Veritas Medical Diagnostics, Inc (IVME)

[~ Blue ~]

IVME receiving huge royalties from NYSE company ALERE

IVME entered into an agreement with Inverness Medical Innovations

From IVME 10Q in 2008

Intellectual Property and Product Development

We have applied for thirteen patents, three of which have been granted. We are currently working on a number of additional patent applications in related areas. Patent protection and management is an important part of our business model.

The first product to be completed using our technology is a prothrombin measurement device, which is used for the measurement of coagulation of blood in patients at risk of heart disease and stroke.

The prothrombin measurement device (the "PT Device") was developed under a research and development contract with Inverness Medical Innovations Inc ("IMI"), which was entered in on November 11, 2002 (the "IMI Agreement"). Pursuant to the IMI Agreement, we are entitled to two types of revenue streams: (i) billings to IMI for our development work during the product development phase and (ii) royalties equal to 2% of net revenues from the sale of the PT Device. The product development phase of the IMI Agreement has been completed. Commercialization of the PT Device by IMI is expected to commence in 2008. IMI will oversee sales and marketing of the prothrombin device and we will not have any influence over this process.

Inverness Medical Innovations Inc has now become Alere Inc.

from their website:

Discover how Inverness Medical Innovations will be adopting the Alere name

http://www.alere.com/en/about-alere.html